A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
Amgen, Inc.
Start Date
February 24, 2026
End Date
June 30, 2030
Administered By
Medicine, Gastroenterology
Awarded By
Amgen, Inc.
Start Date
February 24, 2026
End Date
June 30, 2030